Data for the paper: ‘Effects of different factors on the efficacy of anti PD-(L)1 monotherapy in patients with advanced non-small cell lung cancer: An observational, retrospective cohort study’

Effects of sex, age, EGFR mutation status and smoking status on immunotherapy. we showed that the benefits for PFS and OS were similar in male and female, and in younger (< 65 years of age) and older (≥65 years of age) patients. EGFR mutation status and smoking status are two independent influencing factors. Regardless of EGFR mutation status, the ORR and PFS of current-smokers were better than those of never-smokers; The benefits of immunotherapy for other mutant subtypes except 19del, L858R and T790M were similar to those of EGFR wild-type; Former-smokers are a unique population who benefit poor from immunotherapy than never-smokers or current-smokers.

本数据集旨在探究性别、年龄、表皮生长因子受体（Epidermal Growth Factor Receptor, EGFR）突变状态与吸烟状态对免疫治疗的影响。研究结果显示，男性与女性患者、年龄<65岁的年轻患者与年龄≥65岁的老年患者，其无进展生存期（Progression-Free Survival, PFS）与总生存期（Overall Survival, OS）获益情况相似。EGFR突变状态与吸烟状态为两个独立影响因素：无论EGFR突变状态如何，当前吸烟者的客观缓解率（Objective Response Rate, ORR）与无进展生存期均优于从未吸烟者；除19del、L858R及T790M突变亚型外的其他EGFR突变患者，其免疫治疗获益与EGFR野生型患者相近；既往吸烟者是一类特殊人群，其从免疫治疗中获得的获益劣于从未吸烟者或当前吸烟者。